Related references
Note: Only part of the references are listed.Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo
Xiaolei Ye et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives
Min Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
4-thiazolidinone - A biologically active scaffold
Amit Verma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors
Savithri Ramurthy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells
Hongyu Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Substituent effect on the amino-imino tautomerism of aminothiazoles
Adel A. Mohamed et al.
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
3D-QSAR Studies of Various Diaryl Urea Derivatives of Multi-targeted Receptor Tyrosine Kinase Inhibitors: Molecular Field Analysis Approach
Neha Kansal et al.
LETTERS IN DRUG DESIGN & DISCOVERY (2008)
Design, synthesis, and evaluation of orally active Benzimidazoles and Benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors
Michele H. Potashman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Amino-imino tautomerism of mono- and diaminothiazoles: Quantum chemical study
Adel A. Mohamed et al.
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM (2007)
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor
Yujia Dai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
